Oculis Holding AG

Research Oculis Holding AG (OCS) on Bullrun: market cap USD 790.48M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerOCS
• ExchangeNASDAQ
• CountrySwitzerland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 790.48M
• Financial periodQ1 2026
• Net income-USD 28.85M
• Free cash flow-USD 62.97M

Valuation Snapshot

latest market cap is USD 790.48M.

About Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease;

Frequently asked questions

What is Oculis Holding AG's market cap?

Oculis Holding AG's market capitalization is USD 790.48M.

What does Oculis Holding AG do?

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally.